ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 165

Prevalence of Gout in the Adult Population of France in 2013

Thomas Bardin1, Pierre Clerson2, Stéphane Bouée3, Gerard H. Chales4, Michael Doherty5, René-Marc Flipo6, Charles Lambert7, Frédéric Lioté8, Thierry Poireaud9, Thierry Schaeverbeke10 and Pascal Richette11, 1Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, 2Orgametrie, Roubaix, France, 3Cemka, Bourg la Reine, France, 4Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, 5Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, 6rheumatology, Rene Salengro hospital, Lille, France, 7Ipsen, Boulogne Billancourt, France, 8Hôpital Lariboisière & University Paris Diderot, Paris, France, 9Menarini, Rungis, France, 10Rheumatology, Bordeaux University Hospital, Bordeaux, France, 11INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose The prevalence of gout has been studied in several Western countries by various methods to approach gout diagnosis, and has been estimated to vary from 0.9 to 3.9 %. The prevalence of gout remained unknown in France. The aims of our study was to design a tool that would allow a confident diagnosis of gout in an epidemiological setting and to assess the current prevalence of gout in France.

Methods This was a two phase study. In phase one, we designed a questionnaire to detect gout that would be suitable for telephone interviews by non-physicians. A 62-item questionnaire covering clinical features, co-morbidities and treatment of gout was administered by phone, by non physicians unaware of the patient diagnoses in a case control study. 102 people with crystal-proven gout and 142 controls who had other types of arthritis with no urate crystal in their synovial fluid were included. Logistic regression analysis and classification and regression trees (CARTs) were used to select items discriminating cases from controls. In phase two, a random sample of adults resident in metropolitan France (including Corsica) was derived from the national telephone (fixed and mobile) directory, using the next birthday method in cases of multiple users.  The telephone questionnaire was administered by non-physicians to subjects who acknowledged present or past non traumatic acute pain in a peripheral joint.  The target size for the interview survey was 10,000 participants. Statistical analysis took into account several factors (area, size of the urban centre, sex, age, occupation, known distribution of fixed or mobile users).

Results

In phase one, two logistic regression models (sensitivity 88.0% and 87.5%; specificity 93.0% and 89.8%, respectively) and one CART model (sensitivity 81.4%; specificity 93.7%) revealed 11 informative items that allowed correct classification of 90.0%, 88.8% and 88.5% of patients respectively. In the second phase the response rate varied between 34 % (fixed phone sample) and 38 % (mobile sample). 10,026 participants were interviewed between March and June 2013. 373 declared having suffered from acute, non traumatic joint pain, of whom a diagnosis of gout was made in 84 to 102 subjects, according to the algorithm used. This led to an estimated prevalence of gout of 0.9% ( 95% CI: 0.8, 1.1) in the general population, with no significant geographic variation. Prevalence was greater in men and increased with age. Interestingly prevalence estimate on self declaration only gave a much higher prevalence estimate (3.7%)

Conclusion Gout prevalence in the adult population of metropolitan France in 2013 was estimated to be 0.9%. Studies using self declaration might grossly  overestimate the prevalence of gout.


Disclosure:

T. Bardin,

Novartis, SOBI,

5,

Novartis ,

8;

P. Clerson,

Ipsen, Menarini,

5;

S. Bouée,

Ipsen, Menarini,

5;

G. H. Chales,

Ipsen, Menarini,

5;

M. Doherty,

Manarini,

5;

R. M. Flipo,

Ipsen, Menarini,

5;

C. Lambert,

Ipsen,

3;

F. Lioté,

Celgene Corporation,

2,

Celgene Corporation,

5;

T. Poireaud,

Menarini,

3;

T. Schaeverbeke,
None;

P. Richette,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-gout-in-the-adult-population-of-france-in-2013/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology